Abstract
This document serves as a formal correction to the study "TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT," originally published in Oncotarget in 2017. The correction addresses an image processing error in Figure 2C while reaffirming the study's core findings regarding the oncogenic role of TROP2 in gallbladder cancer (GBC).
Introduction
Gallbladder cancer (GBC) is a notoriously aggressive malignancy, often diagnosed at advanced stages with a high propensity for metastasis. Understanding the molecular mechanisms that drive GBC progression is critical for developing effective therapies. This research focuses on Trophoblast cell-surface antigen 2 (TROP2), a transmembrane glycoprotein frequently overexpressed in epithelial tumors. The study investigates whether TROP2 functions as a key driver of GBC by regulating the PI3K/AKT signaling pathway and inducing the Epithelial-Mesenchymal Transition (EMT).
Experimental Approach
The researchers utilized five human GBC cell lines—NOZ, GBC-SD, OCUG-1, SGC-996, and EH-GB-1—to profile TROP2 expression and evaluate its functional impact.
- Expression Profiling: Protein levels were assessed via Western Blotting, and mRNA levels were quantified using quantitative PCR (qPCR).
- Functional Modulation: To establish causality, TROP2 was either silenced using RNA interference (shRNA) or overexpressed via plasmid transfection.
- Validation: RT-PCR was employed to verify the success of these genetic manipulations, specifically in the GBC-SD and SGC-996 lines.
Results and Key Insights
The study revealed significant variability in TROP2 expression across GBC cell lines. Notably, GBC-SD and SGC-996 exhibited the highest levels of TROP2 mRNA and protein, suggesting that TROP2 may be a particularly relevant therapeutic target in specific GBC subtypes.
TROP2 and the PI3K/AKT Pathway
The data indicates a direct link between TROP2 and the PI3K/AKT pathway, a central regulator of cell survival and growth. By maintaining this pathway in an active state, TROP2 promotes the rapid proliferation of cancer cells.
Induction of EMT and Metastasis
TROP2 was found to trigger EMT, a process where stationary epithelial cells transform into migratory mesenchymal cells. This "reprogramming" allows cancer cells to detach from the primary tumor and invade surrounding tissues, facilitating metastasis.
Correction of Figure 2C
The authors identified that an incorrect image was originally used for the GBC-SD cell line in Figure 2C. The corrected figure (shown above in panel C) provides the accurate RT-PCR results for both GBC-SD and SGC-996. These corrected data are consistent with the original conclusions: silencing TROP2 (shTROP2) effectively reduces its expression, while plasmid transfection significantly increases it, correlating with changes in cellular aggressiveness.
Conclusion
Despite the initial error in image assembly, the fundamental conclusions of the study remain robust. TROP2 acts as a master regulator in GBC, driving proliferation and metastasis through the PI3K/AKT pathway and EMT induction. Future research should focus on validating these findings in in vivo models and exploring the clinical potential of TROP2-targeted therapies.
Summary updated